Experience
Genzyme Corporation et al.
Novartis Gene Therapies, Inc. et al.
Defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al., 1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Novartis Pharmaceuticals Corporation et al.
Aerin Medical Inc. et al. v. Neurent Medical Inc. et al.
Aerin Medical Inc. et al.
Zimmer Surgical, Inc. et al. v. Stryker Corporation et al.
Zimmer Surgical, Inc.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
AbbVie Inc.
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
Grünenthal GmbH et al.
BioDelivery Sciences International, Inc. et al. v. Chemo Research, SL et al.
BioDelivery Sciences International, Inc. et al.
Välinge Innovation AB v. Halstead New England Corporation, The Home Depot Inc. et al.
Välinge Innovation AB
AbbVie Inc. et al v. Alvotech hf.
AbbVie Inc. et al
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.